SEC Comment Letter for Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Aug 26, 2019
Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Aug. 26, 2019 · CIK: 0001645469 · Accession: 0000000000-19-012858
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233303
Letter
August 26, 2019 Chandler Robinson Chief Executive Officer Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, IL 60091 Re:Monopar Therapeutics Inc. Registration Statement on Form S-3 Filed August 15, 2019 File No. 333-233303 Dear Dr. Robinson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Sonia Bednarowski at 202-551-3666 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
August 26, 2019
Chandler Robinson
Chief Executive Officer
Monopar Therapeutics Inc.
1000 Skokie Blvd., Suite 350
Wilmette, IL 60091
Re:Monopar Therapeutics Inc.
Registration Statement on Form S-3
Filed August 15, 2019
File No. 333-233303
Dear Dr. Robinson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Sonia Bednarowski at 202-551-3666 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance